NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 03 01:30PM ET
2.72
Dollar change
+0.03
Percentage change
1.12
%
Index- P/E- EPS (ttm)-3.18 Insider Own5.44% Shs Outstand1.49M Perf Week3.03%
Market Cap4.06M Forward P/E1.83 EPS next Y1.49 Insider Trans-0.05% Shs Float1.41M Perf Month-24.44%
Enterprise Value-3.42M PEG- EPS next Q-0.30 Inst Own16.22% Short Float1.26% Perf Quarter5.02%
Income-5.08M P/S0.35 EPS this Y64.06% Inst Trans42.72% Short Ratio1.08 Perf Half Y-42.98%
Sales11.59M P/B0.70 EPS next Y247.52% ROA-35.23% Short Interest0.02M Perf YTD-38.46%
Book/sh3.91 P/C0.32 EPS next 5Y- ROE-108.77% 52W High12.32 -77.92% Perf Year-51.96%
Cash/sh8.44 P/FCF- EPS past 3/5Y58.10% 42.83% ROIC-85.72% 52W Low1.94 40.21% Perf 3Y-92.57%
Dividend Est.- EV/EBITDA- Sales past 3/5Y85.03% - Gross Margin97.36% Volatility4.26% 8.96% Perf 5Y-99.47%
Dividend TTM- EV/Sales-0.29 EPS Y/Y TTM85.54% Oper. Margin-43.17% ATR (14)0.22 Perf 10Y-99.67%
Dividend Ex-Date- Quick Ratio1.50 Sales Y/Y TTM89.89% Profit Margin-43.80% RSI (14)43.43 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio1.55 EPS Q/Q75.45% SMA20-3.46% Beta-0.08 Target Price18.00
Payout- Debt/Eq0.88 Sales Q/Q77.48% SMA50-10.70% Rel Volume1.53 Prev Close2.69
Employees3 LT Debt/Eq0.01 EarningsMay 13 AMC SMA200-32.96% Avg Volume16.39K Price2.72
IPOSep 25, 2013 Option/ShortNo / Yes EPS/Sales Surpr.-54.55% -7.11% Trades Volume25,028 Change1.12%
Date Action Analyst Rating Change Price Target Change
Jun-22-20Upgrade H.C. Wainwright Neutral → Buy $10
Mar-05-19Downgrade H.C. Wainwright Buy → Neutral
Mar-08-18Reiterated B. Riley FBR, Inc. Buy $10 → $5
Oct-19-17Resumed FBR & Co. Buy $10
Mar-16-17Reiterated Rodman & Renshaw Buy $6 → $9
Jan-30-17Upgrade Laidlaw Neutral → Buy $8
Jan-05-17Upgrade Rodman & Renshaw Neutral → Buy $2.50 → $6
Dec-23-16Reiterated Rodman & Renshaw Neutral $2 → $2.50
Jul-19-16Reiterated FBR Capital Outperform $17 → $9
Jul-19-16Downgrade Noble Financial Buy → Hold
May-13-25 04:05PM
Apr-28-25 08:30AM
Mar-14-25 01:44PM
03:09AM
Mar-13-25 04:02PM
08:30AM Loading…
Mar-06-25 08:30AM
Feb-24-25 08:30AM
Jan-06-25 08:58AM
Dec-19-24 08:30AM
Dec-03-24 08:30AM
Nov-07-24 04:05PM
Oct-28-24 01:39PM
07:00AM
Oct-23-24 08:30AM
Oct-22-24 08:30AM
08:30AM Loading…
Oct-01-24 08:30AM
Sep-21-24 02:38AM
Sep-19-24 02:20PM
Sep-09-24 08:30AM
Sep-04-24 09:20AM
Aug-13-24 08:00AM
Aug-08-24 08:30AM
Jul-30-24 08:30AM
Jun-17-24 08:30AM
May-16-24 04:02PM
May-14-24 10:53PM
04:15PM
Apr-17-24 08:30AM
Mar-21-24 04:15PM
Mar-15-24 01:58PM
06:56AM Loading…
06:56AM
Mar-14-24 04:05PM
Mar-07-24 04:10PM
Feb-14-24 07:30AM
Feb-09-24 07:30AM
Nov-30-23 12:16PM
Nov-27-23 08:30AM
Nov-14-23 08:30AM
Nov-09-23 08:30AM
Oct-31-23 08:30AM
Oct-23-23 06:30AM
Oct-18-23 08:30AM
Sep-14-23 08:30AM
Aug-10-23 08:30AM
Aug-07-23 08:30AM
Jul-25-23 08:30AM
Jun-14-23 08:30AM
May-15-23 04:05PM
May-09-23 07:00AM
May-04-23 08:30AM
May-01-23 08:30AM
Apr-20-23 08:30AM
Apr-06-23 08:30AM
Mar-24-23 07:36AM
Mar-23-23 08:30AM
Mar-21-23 04:05PM
Mar-15-23 08:30AM
Feb-21-23 07:00AM
Jan-30-23 07:00AM
Jan-18-23 08:30AM
Dec-07-22 08:30AM
Nov-30-22 08:30AM
Nov-12-22 08:03AM
Nov-09-22 04:30PM
04:05PM
Nov-02-22 08:30AM
Oct-20-22 08:44AM
Sep-20-22 08:30AM
Sep-14-22 08:30AM
Sep-06-22 08:30AM
Aug-16-22 08:30AM
Aug-10-22 04:30PM
04:05PM
Aug-03-22 08:30AM
Aug-01-22 08:30AM
Jul-06-22 08:30AM
Jun-15-22 08:30AM
Jun-08-22 08:30AM
May-23-22 07:00AM
May-18-22 08:30AM
May-17-22 08:30AM
May-10-22 04:05PM
May-03-22 08:30AM
Apr-26-22 11:36AM
08:54AM
08:30AM
Apr-19-22 08:30AM
Mar-10-22 08:30AM
Mar-08-22 04:05PM
Mar-01-22 08:30AM
Feb-24-22 08:30AM
Feb-17-22 08:30AM
Feb-02-22 08:30AM
Jan-04-22 08:30AM
Nov-10-21 04:05PM
Nov-03-21 08:30AM
Oct-20-21 08:30AM
Sep-29-21 08:30AM
Sep-10-21 07:53AM
Sep-01-21 08:30AM
Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It also develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Nantahala Capital Management, 10% OwnerJan 28 '25Sale4.3941180148,153Jan 30 06:39 PM